CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

Natural killer (NK) cells play an important role in the immunosurveillance of leukemia. Their reactivity is governed by a balance of activating and inhibitory receptors including various members of the tumor necrosis factor receptor (TNFR) family. Here we report that human NK cells acquire expression of the TNFR family member CD137 upon activation, and NK cells of acute myeloid leukemia (AML) patients display an activated phenotype with substantial CD137 expression. CD137 ligand (CD137L) was detectable on leukemic cells in 35% of 65 investigated AML patients, but not on healthy CD34(+) cells, and expression was associated with monocytic differentiation. Bidirectional signaling following CD137-CD137L interaction induced the release of the immunomodulatory cytokines interleukin-10 and TNF by AML cells and directly diminished granule mobilization, cytotoxicity, and interferon-gamma production of human NK cells, which was restored by blocking CD137. Cocultures of NK cells with CD137L transfectants confirmed that human CD137 inhibits NK-cell reactivity, while activating signals were transduced by its counterpart on NK cells in mice. Our data underline the necessity to study the function of seemingly analog immunoregulatory molecules in mice compared with men and demonstrate that CD137-CD137L interaction enables immune evasion of AML cells by impairing NK-cell tumor surveillance in humans.

[1]  M. Croft.  The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.

[2]  H. Salih,et al.  Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. , 2009, Cancer research.

[3]  A. Bringmann,et al.  Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. , 2008, Blood.

[4]  H. Schwarz,et al.  CD137 Induces Proliferation of Murine Hematopoietic Progenitor Cells and Differentiation to Macrophages1 , 2008, The Journal of Immunology.

[5]  H. Schwarz,et al.  Induction of Proliferation and Monocytic Differentiation of Human CD34+ Cells by CD137 Ligand Signaling , 2008, Stem cells.

[6]  F. Locatelli,et al.  Human NK cells: from HLA class I‐specific killer Ig‐like receptors to the therapy of acute leukemias , 2008, Immunological reviews.

[7]  Lai-Xi Wang,et al.  Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. , 2008, Blood.

[8]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[9]  B. Kwon,et al.  Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells , 2008, Nature Immunology.

[10]  L. Zitvogel,et al.  Natural killer cell–directed therapies: moving from unexpected results to successful strategies , 2008, Nature Immunology.

[11]  Lewis L Lanier,et al.  Up on the tightrope: natural killer cell activation and inhibition , 2008, Nature Immunology.

[12]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[13]  D. Lynch.  The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer , 2008, Immunological reviews.

[14]  J. McNamara,et al.  Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. , 2008, The Journal of clinical investigation.

[15]  H. Rammensee,et al.  Cancer immunoediting by GITR (glucocorticoid‐induced TNF‐related protein) ligand in humans: NK cell/tumor cell interactions , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  H. Ljunggren,et al.  Prospects for the use of NK cells in immunotherapy of human cancer , 2007, Nature Reviews Immunology.

[17]  Z. Ye,et al.  Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. , 2007, Cancer research.

[18]  Drew M. Pardoll,et al.  Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.

[19]  T. D. de Gruijl,et al.  Leukemia-Specific T-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1BB Targeting , 2007, Clinical Cancer Research.

[20]  D. Jarjoura,et al.  Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. , 2006, Cancer research.

[21]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[22]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[23]  Walter Kolch,et al.  Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. , 2004, Cytokine & growth factor reviews.

[24]  P. Maes,et al.  Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? , 2004, Blood.

[25]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[26]  M. Binaschi,et al.  CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival , 2004, International journal of cancer.

[27]  G. Pierson,et al.  Deficient expression of class-I HLA in some cases of acute leukemia , 2004, Cancer Immunology, Immunotherapy.

[28]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[29]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[30]  M. Glennie,et al.  Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4‐1BB), and their role in the generation of anti‐tumor immune responses , 2002, European journal of immunology.

[31]  Manuela Battaglia,et al.  Human CD25+CD4+ T Suppressor Cell Clones Produce Transforming Growth Factor β, but not Interleukin 10, and Are Distinct from Type 1 T Regulatory Cells , 2002, The Journal of experimental medicine.

[32]  Lieping Chen,et al.  Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity1 , 2002, The Journal of Immunology.

[33]  B. Kwon,et al.  Molecular cloning of agonistic and antagonistic monoclonal antibodies against human 4-1BB. , 2002, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[34]  N. Boiani,et al.  4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner , 2002, The Journal of Immunology.

[35]  Lieping Chen,et al.  Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. , 2002, Cancer research.

[36]  S. Thung,et al.  T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer , 2002, Gene Therapy.

[37]  M. Lowdell,et al.  Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells , 2002, British journal of haematology.

[38]  A. Dahlin,et al.  Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB , 2002, Nature Medicine.

[39]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[40]  Aaron J. Johnson,et al.  Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. , 2002, The Journal of clinical investigation.

[41]  Peter Lipsky,et al.  Cytokines and autoimmunity , 2002, Nature Reviews Immunology.

[42]  P. Kiener,et al.  Soluble CD137 (4-1BB) Ligand Is Released Following Leukocyte Activation and Is Found in Sera of Patients with Hematological Malignancies1 , 2001, The Journal of Immunology.

[43]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[44]  F. Lee,et al.  Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells1 , 2000, The Journal of Immunology.

[45]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[46]  Lieping Chen,et al.  NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. , 1998, Cellular immunology.

[47]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[48]  J. Miller,et al.  CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. , 1996, Blood.

[49]  H. Kawasaki,et al.  Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. , 1996, Leukemia.